About: Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.37 (-6.11%)
KTTA NASDAQ Pasithea Therapeutics Corp
Pasithea Therapeutics Corp share price
Atividade de preço de KTTA
Último preço
$ 0,370
Variação (24h)
-0,02 USD (6,11%)
Volume
10.45K
Volume (média 4 sem.)
-
Fechamento anterior
$ 0,39
Último negócio
29 Oct, 1:33 pm GMT+0
Atrasado
29 Oct, 1:33 pm GMT+0
KTTA price performance
Atrasado
29 Oct, 1:33 pm GMT+0
quote.marketSignals